The present disclosure is directed to methods for treating a solid cancerous cancer through administering a bispecific anti-PDl x anti- CTLA4 antibody.La présente invention concerne des méthodes de traitement d'un cancer de type tumeur maligne solide par administration d'un anticorps bispécifique anti-PDl x anti- CTLA4.